PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25860284-2 2015 We have previously reported that the combination of the EGFR-TKI erlotinib and epigallocatechin-3-gallate (EGCG) exhibited synergistic chemopreventive effects in head and neck cancers by inducing the expression of Bim, p21, p27, and by inhibiting the phosphorylation of ERK and AKT and expression of Bcl-2. epigallocatechin gallate 107-111 epidermal growth factor receptor Homo sapiens 56-60 26077136-5 2015 Our profiling reveals that RA and EGCG selectively inhibit 3% (EGFR and SYK) and 14% of 64 kinases, respectively. epigallocatechin gallate 34-38 epidermal growth factor receptor Homo sapiens 63-67 25263976-2 2014 In these studies, EGCG usually inhibits EGFR, and impairs the ERK1/2 phosphorylation in tumor cells. epigallocatechin gallate 18-22 epidermal growth factor receptor Homo sapiens 40-44 25591943-3 2015 EGCG dose-dependently inhibited anchorage-independent growth and short-term EGCG exposure substantially decreased EGF-induced EGF receptor (EGFR), Akt and ERK1/2 activation, as well as the downregulation of hexokinase 2 (HK2). epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 126-138 25591943-3 2015 EGCG dose-dependently inhibited anchorage-independent growth and short-term EGCG exposure substantially decreased EGF-induced EGF receptor (EGFR), Akt and ERK1/2 activation, as well as the downregulation of hexokinase 2 (HK2). epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 140-144 25591943-3 2015 EGCG dose-dependently inhibited anchorage-independent growth and short-term EGCG exposure substantially decreased EGF-induced EGF receptor (EGFR), Akt and ERK1/2 activation, as well as the downregulation of hexokinase 2 (HK2). epigallocatechin gallate 76-80 epidermal growth factor receptor Homo sapiens 126-138 25591943-3 2015 EGCG dose-dependently inhibited anchorage-independent growth and short-term EGCG exposure substantially decreased EGF-induced EGF receptor (EGFR), Akt and ERK1/2 activation, as well as the downregulation of hexokinase 2 (HK2). epigallocatechin gallate 76-80 epidermal growth factor receptor Homo sapiens 140-144 24366444-0 2014 Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway. epigallocatechin gallate 0-24 epidermal growth factor receptor Homo sapiens 92-96 24508477-9 2014 Both curcumin and EGCG effectively reduced acrylamide-induced proliferation, as well as protein expression of CYP2E1, EGFR, cyclin D1 and NF-kappaB. epigallocatechin gallate 18-22 epidermal growth factor receptor Homo sapiens 118-122 24366444-5 2014 The mechanism underlying EGCG antitumor potency was mainly dependent on suppression of the EGFR signaling pathway. epigallocatechin gallate 25-29 epidermal growth factor receptor Homo sapiens 91-95 24366444-6 2014 Short-term EGCG exposure substantially decreased EGF-induced EGFR, AKT and ERK1/2 activation. epigallocatechin gallate 11-15 epidermal growth factor receptor Homo sapiens 61-65 24366444-7 2014 Moreover, long-term EGCG treatment not only inhibited total and membranous EGFR expression, but also markedly attenuated EGFR nuclear localization and expression of the downstream target gene cyclin D1, indicating that EGCG treatment suppressed EGFR transactivation. epigallocatechin gallate 20-24 epidermal growth factor receptor Homo sapiens 75-79 24366444-7 2014 Moreover, long-term EGCG treatment not only inhibited total and membranous EGFR expression, but also markedly attenuated EGFR nuclear localization and expression of the downstream target gene cyclin D1, indicating that EGCG treatment suppressed EGFR transactivation. epigallocatechin gallate 20-24 epidermal growth factor receptor Homo sapiens 121-125 24366444-7 2014 Moreover, long-term EGCG treatment not only inhibited total and membranous EGFR expression, but also markedly attenuated EGFR nuclear localization and expression of the downstream target gene cyclin D1, indicating that EGCG treatment suppressed EGFR transactivation. epigallocatechin gallate 20-24 epidermal growth factor receptor Homo sapiens 121-125 24366444-7 2014 Moreover, long-term EGCG treatment not only inhibited total and membranous EGFR expression, but also markedly attenuated EGFR nuclear localization and expression of the downstream target gene cyclin D1, indicating that EGCG treatment suppressed EGFR transactivation. epigallocatechin gallate 219-223 epidermal growth factor receptor Homo sapiens 121-125 24366444-7 2014 Moreover, long-term EGCG treatment not only inhibited total and membranous EGFR expression, but also markedly attenuated EGFR nuclear localization and expression of the downstream target gene cyclin D1, indicating that EGCG treatment suppressed EGFR transactivation. epigallocatechin gallate 219-223 epidermal growth factor receptor Homo sapiens 121-125 24366444-8 2014 Additionally, knockdown of EGFR in lung cancer cells decreased their sensitivity to EGCG. epigallocatechin gallate 84-88 epidermal growth factor receptor Homo sapiens 27-31 24366444-9 2014 Thus, inhibition of the EGFR signaling pathway may partly contribute to the anticancer activity of EGCG. epigallocatechin gallate 99-103 epidermal growth factor receptor Homo sapiens 24-28 24456004-0 2014 Epigallocatechin 3-O-gallate induces 67 kDa laminin receptor-mediated cell death accompanied by downregulation of ErbB proteins and altered lipid raft clustering in mammary and epidermoid carcinoma cells. epigallocatechin gallate 0-28 epidermal growth factor receptor Homo sapiens 114-118 24798568-5 2014 Although the expression level of Gli-1 was markedly downregulated by cyclopamine treatment, treatment with EGCG significantly inhibited the phosphorylation of EGFR in Mia PaCa-2 cells. epigallocatechin gallate 107-111 epidermal growth factor receptor Homo sapiens 159-163 21725973-0 2011 Epigallocatechin-3-gallate induces growth inhibition and apoptosis of human anaplastic thyroid carcinoma cells through suppression of EGFR/ERK pathway and cyclin B1/CDK1 complex. epigallocatechin gallate 0-26 epidermal growth factor receptor Homo sapiens 134-138 22923287-10 2012 Importantly, EGCG sensitizes CAL-27 cells to gefitinib-suppressed phosphorylation of epidermal growth factor receptor (EGFR in vitro. epigallocatechin gallate 13-17 epidermal growth factor receptor Homo sapiens 85-117 22923287-10 2012 Importantly, EGCG sensitizes CAL-27 cells to gefitinib-suppressed phosphorylation of epidermal growth factor receptor (EGFR in vitro. epigallocatechin gallate 13-17 epidermal growth factor receptor Homo sapiens 119-123 22923287-0 2012 Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2. epigallocatechin gallate 0-24 epidermal growth factor receptor Homo sapiens 192-224 22923287-8 2012 Furthermore, individual or combined treatment with EGCG and gefitinib suppressed the protein expression of p-EGFR and the phosphorylated protein levels of ERK, JNK, p38 and AKT and displayed inhibitory effects on metastatic ability of CAL-27 cells. epigallocatechin gallate 51-55 epidermal growth factor receptor Homo sapiens 109-113 22769244-7 2012 Treating lung cancer cells with EGCG or C75 induced apoptosis and affected EGFR-signaling. epigallocatechin gallate 32-36 epidermal growth factor receptor Homo sapiens 75-79 22769244-8 2012 While EGCG abolished p-EGFR, p-AKT, p-ERK1/2 and p-mTOR, C75 was less active in decreasing the levels of EGFR and p-AKT. epigallocatechin gallate 6-10 epidermal growth factor receptor Homo sapiens 23-27 22769244-10 2012 CONCLUSIONS: In lung cancer, inhibition of FASN using EGCG can be achieved without parallel stimulation of fatty acid oxidation and this effect is related mainly to EGFR signaling pathway. epigallocatechin gallate 54-58 epidermal growth factor receptor Homo sapiens 165-169 21725973-7 2011 Inhibition of EGFR/MAPK pathway and cell cycle-related proteins by EGCG were measured by Western blot analysis. epigallocatechin gallate 67-71 epidermal growth factor receptor Homo sapiens 14-18 21725973-10 2011 Furthermore, EGCG suppressed phosphorylation of EGFR, ERK1/2, JNK, and p38. epigallocatechin gallate 13-17 epidermal growth factor receptor Homo sapiens 48-52 21725973-13 2011 CONCLUSIONS: Taken together, EGCG inhibits cell proliferation and induces apoptosis via suppression of the EGFR/ERK pathway and cyclin B1/CDK1 complex in ATC cells. epigallocatechin gallate 29-33 epidermal growth factor receptor Homo sapiens 107-111 21391127-8 2011 The major signaling pathways affected by GTE and EGCG were EGFR and Notch pathways, which, in turn, affected cell cycle-related networks. epigallocatechin gallate 41-44 epidermal growth factor receptor Homo sapiens 59-63 21538846-2 2011 (-)-Epigallocatechin-3-gallate (EGCG), the major catechin in green tea, inhibits cell proliferation and induces apoptosis in various types of cancer cells, including colorectal cancer and hepatocellular carcinoma cells, by blocking the activation of the epidermal growth factor receptor (EGFR) family of RTKs. epigallocatechin gallate 0-30 epidermal growth factor receptor Homo sapiens 254-286 21538846-2 2011 (-)-Epigallocatechin-3-gallate (EGCG), the major catechin in green tea, inhibits cell proliferation and induces apoptosis in various types of cancer cells, including colorectal cancer and hepatocellular carcinoma cells, by blocking the activation of the epidermal growth factor receptor (EGFR) family of RTKs. epigallocatechin gallate 0-30 epidermal growth factor receptor Homo sapiens 288-292 21538846-2 2011 (-)-Epigallocatechin-3-gallate (EGCG), the major catechin in green tea, inhibits cell proliferation and induces apoptosis in various types of cancer cells, including colorectal cancer and hepatocellular carcinoma cells, by blocking the activation of the epidermal growth factor receptor (EGFR) family of RTKs. epigallocatechin gallate 32-36 epidermal growth factor receptor Homo sapiens 254-286 21538846-2 2011 (-)-Epigallocatechin-3-gallate (EGCG), the major catechin in green tea, inhibits cell proliferation and induces apoptosis in various types of cancer cells, including colorectal cancer and hepatocellular carcinoma cells, by blocking the activation of the epidermal growth factor receptor (EGFR) family of RTKs. epigallocatechin gallate 32-36 epidermal growth factor receptor Homo sapiens 288-292 21538846-4 2011 EGCG suppresses the activation of EGFR in part by altering membrane lipid organization and causing the subsequent inhibition of the dimerization and activation of this receptor. epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 34-38 20446926-0 2011 (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. epigallocatechin gallate 0-30 epidermal growth factor receptor Homo sapiens 46-50 20446926-2 2011 As EGCG [(-)-epigallocatechin-3-gallate], the most active catechin present in green tea, has been shown to down-regulate EGFR, we studied the effects of 10-100 mug/ml EGCG treatment on growth and invasion in a breast carcinoma cell line resistant to tamoxifen [MCF-7Tam (MCF-7 breast carcinoma cell line resistant to tamoxifen) cells] and parental MCF-7. epigallocatechin gallate 3-7 epidermal growth factor receptor Homo sapiens 121-125 20446926-2 2011 As EGCG [(-)-epigallocatechin-3-gallate], the most active catechin present in green tea, has been shown to down-regulate EGFR, we studied the effects of 10-100 mug/ml EGCG treatment on growth and invasion in a breast carcinoma cell line resistant to tamoxifen [MCF-7Tam (MCF-7 breast carcinoma cell line resistant to tamoxifen) cells] and parental MCF-7. epigallocatechin gallate 9-39 epidermal growth factor receptor Homo sapiens 121-125 20446926-3 2011 A dose-dependent down-regulation of EGFR mRNA expression and protein level occurred after 50 mug/ml EGCG treatment of MCF-7Tam cells. epigallocatechin gallate 100-104 epidermal growth factor receptor Homo sapiens 36-40 20446926-5 2011 EGFR phosphorylation (Tyr-992, Tyr-1045 and Tyr-1068) was higher in MCF-7Tam than in MCF-7 and it was reduced by EGCG treatment. epigallocatechin gallate 113-117 epidermal growth factor receptor Homo sapiens 0-4 20446926-10 2011 EGCG could stop MCF-7Tam cell growth and in vitro invasion through down-regulation of EGFR and other molecules implicated in aggressive biological behaviour. epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 86-90 21391127-8 2011 The major signaling pathways affected by GTE and EGCG were EGFR and Notch pathways, which, in turn, affected cell cycle-related networks. epigallocatechin gallate 49-53 epidermal growth factor receptor Homo sapiens 59-63 19325845-6 2008 EGCG inhibits the activation of EGFR (erbB1), HER2 (neu/erbB2) and also HER3 (neu/erbB3), which belong to subclass I of the RTK superfamily, in various types of human cancer cells. epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 32-36 19578043-1 2009 We previously reported that (-)-epigallocatechin gallate (EGCG) in green tea alters plasma membrane organization and causes internalization of epidermal growth factor receptor (EGFR), resulting in the suppression of colon cancer cell growth. epigallocatechin gallate 28-56 epidermal growth factor receptor Homo sapiens 143-175 19578043-1 2009 We previously reported that (-)-epigallocatechin gallate (EGCG) in green tea alters plasma membrane organization and causes internalization of epidermal growth factor receptor (EGFR), resulting in the suppression of colon cancer cell growth. epigallocatechin gallate 28-56 epidermal growth factor receptor Homo sapiens 177-181 19578043-1 2009 We previously reported that (-)-epigallocatechin gallate (EGCG) in green tea alters plasma membrane organization and causes internalization of epidermal growth factor receptor (EGFR), resulting in the suppression of colon cancer cell growth. epigallocatechin gallate 58-62 epidermal growth factor receptor Homo sapiens 143-175 19578043-1 2009 We previously reported that (-)-epigallocatechin gallate (EGCG) in green tea alters plasma membrane organization and causes internalization of epidermal growth factor receptor (EGFR), resulting in the suppression of colon cancer cell growth. epigallocatechin gallate 58-62 epidermal growth factor receptor Homo sapiens 177-181 19578043-2 2009 In the present study, we investigated the detailed mechanism underlying EGCG-induced downregulation of EGFR in SW480 colon cancer cells. epigallocatechin gallate 72-76 epidermal growth factor receptor Homo sapiens 103-107 19578043-3 2009 Prolonged exposure to EGCG caused EGFR degradation. epigallocatechin gallate 22-26 epidermal growth factor receptor Homo sapiens 34-38 19578043-5 2009 In addition, EGCG induced phosphorylation of p38 mitogen-activated protein kinase (MAPK), a stress-inducible kinase believed to negatively regulate tumorigenesis, and the inhibition of p38 MAPK by SB203580, a specific p38 MAPK inhibitor, or the gene silencing using p38 MAPK-small interfering RNA (siRNA) suppressed the internalization and subsequent degradation of EGFR induced by EGCG. epigallocatechin gallate 13-17 epidermal growth factor receptor Homo sapiens 366-370 19578043-6 2009 EGFR underwent a gel mobility shift upon treatment with EGCG and this was canceled by SB203580, indicating that EGCG causes EGFR phosphorylation via p38 MAPK. epigallocatechin gallate 56-60 epidermal growth factor receptor Homo sapiens 0-4 19578043-6 2009 EGFR underwent a gel mobility shift upon treatment with EGCG and this was canceled by SB203580, indicating that EGCG causes EGFR phosphorylation via p38 MAPK. epigallocatechin gallate 56-60 epidermal growth factor receptor Homo sapiens 124-128 19578043-6 2009 EGFR underwent a gel mobility shift upon treatment with EGCG and this was canceled by SB203580, indicating that EGCG causes EGFR phosphorylation via p38 MAPK. epigallocatechin gallate 112-116 epidermal growth factor receptor Homo sapiens 0-4 19578043-6 2009 EGFR underwent a gel mobility shift upon treatment with EGCG and this was canceled by SB203580, indicating that EGCG causes EGFR phosphorylation via p38 MAPK. epigallocatechin gallate 112-116 epidermal growth factor receptor Homo sapiens 124-128 19578043-7 2009 Moreover, EGCG caused phosphorylation of EGFR at Ser1046/1047, a site that is critical for its downregulation and this was also suppressed by SB203580 or siRNA of p38 MAPK. epigallocatechin gallate 10-14 epidermal growth factor receptor Homo sapiens 41-45 19578043-8 2009 Taken together, our results strongly suggest that phosphorylation of EGFR at serine 1046/1047 via activation of p38 MAPK plays a pivotal role in EGCG-induced downregulation of EGFR in colon cancer cells. epigallocatechin gallate 145-149 epidermal growth factor receptor Homo sapiens 69-73 19578043-8 2009 Taken together, our results strongly suggest that phosphorylation of EGFR at serine 1046/1047 via activation of p38 MAPK plays a pivotal role in EGCG-induced downregulation of EGFR in colon cancer cells. epigallocatechin gallate 145-149 epidermal growth factor receptor Homo sapiens 176-180 19261982-6 2008 Similar to aplidin and edelfosin, EGCG alters membrane domains composition also preventing EGF binding to EGFR, imerization of EGFR and relocation of phosphorylated EGFR to lipid rafts. epigallocatechin gallate 34-38 epidermal growth factor receptor Homo sapiens 106-110 19261982-6 2008 Similar to aplidin and edelfosin, EGCG alters membrane domains composition also preventing EGF binding to EGFR, imerization of EGFR and relocation of phosphorylated EGFR to lipid rafts. epigallocatechin gallate 34-38 epidermal growth factor receptor Homo sapiens 127-131 19261982-6 2008 Similar to aplidin and edelfosin, EGCG alters membrane domains composition also preventing EGF binding to EGFR, imerization of EGFR and relocation of phosphorylated EGFR to lipid rafts. epigallocatechin gallate 34-38 epidermal growth factor receptor Homo sapiens 127-131 18586691-0 2008 (-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells. epigallocatechin gallate 0-28 epidermal growth factor receptor Homo sapiens 59-91 18586691-1 2008 We recently found that the inhibitory effect of (-)-epigallocatechin gallate (EGCG) on epidermal growth factor (EGF) binding to the epidermal growth factor receptor (EGFR) is associated with alterations in lipid organization in the plasma membrane of colon cancer cells. epigallocatechin gallate 48-76 epidermal growth factor receptor Homo sapiens 132-164 18586691-1 2008 We recently found that the inhibitory effect of (-)-epigallocatechin gallate (EGCG) on epidermal growth factor (EGF) binding to the epidermal growth factor receptor (EGFR) is associated with alterations in lipid organization in the plasma membrane of colon cancer cells. epigallocatechin gallate 48-76 epidermal growth factor receptor Homo sapiens 166-170 18586691-1 2008 We recently found that the inhibitory effect of (-)-epigallocatechin gallate (EGCG) on epidermal growth factor (EGF) binding to the epidermal growth factor receptor (EGFR) is associated with alterations in lipid organization in the plasma membrane of colon cancer cells. epigallocatechin gallate 78-82 epidermal growth factor receptor Homo sapiens 132-164 18586691-1 2008 We recently found that the inhibitory effect of (-)-epigallocatechin gallate (EGCG) on epidermal growth factor (EGF) binding to the epidermal growth factor receptor (EGFR) is associated with alterations in lipid organization in the plasma membrane of colon cancer cells. epigallocatechin gallate 78-82 epidermal growth factor receptor Homo sapiens 166-170 18586691-2 2008 Since changes in lipid organizations are thought to play a role in the trafficking of several membrane proteins, in this study we examined the effects of EGCG on cellular localization of the EGFR in SW480 cells. epigallocatechin gallate 154-158 epidermal growth factor receptor Homo sapiens 191-195 18586691-5 2008 As expected, the EGFR protein was phosphorylated at tyrosine residues, ubiquitinated and partially degraded when the cells were treated with EGF, but treatment with EGCG caused none of these effects. epigallocatechin gallate 165-169 epidermal growth factor receptor Homo sapiens 17-21 18586691-7 2008 This sequestrating of inactivated EGFRs into endosomes may explain, at least in part, the ability of EGCG to inhibit activation of the EGFR and thereby exert anticancer effects. epigallocatechin gallate 101-105 epidermal growth factor receptor Homo sapiens 34-38 19325845-6 2008 EGCG inhibits the activation of EGFR (erbB1), HER2 (neu/erbB2) and also HER3 (neu/erbB3), which belong to subclass I of the RTK superfamily, in various types of human cancer cells. epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 38-43 19325845-8 2008 In addition, EGCG alters membrane lipid organization and thus inhibits the dimerization and activation of EGFR. epigallocatechin gallate 13-17 epidermal growth factor receptor Homo sapiens 106-110 17616711-0 2007 The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. epigallocatechin gallate 25-53 epidermal growth factor receptor Homo sapiens 75-107 18618485-0 2008 Comparison of delphinidin, quercetin and (-)-epigallocatechin-3-gallate as inhibitors of the EGFR and the ErbB2 receptor phosphorylation. epigallocatechin gallate 41-71 epidermal growth factor receptor Homo sapiens 93-97 17569617-4 2007 Specifically, EGCG regulates expression of VEGF, matrix metalloproteinases, uPA, IGF-1, EGFR, cell cycle regulatory proteins and inhibits NFk B, PI3-K/Akt, Ras/Raf/MAPK and AP-1 signaling pathways, thereby causing strong cancer chemopreventive effects. epigallocatechin gallate 14-18 epidermal growth factor receptor Homo sapiens 88-92 17616711-1 2007 (-)-Epigallocatechin gallate (EGCG), a major biologically active constituent of green tea, inhibits activation of the epidermal growth factor (EGF) receptor (EGFR) and downstream signaling pathways in several types of human cancer cells, but the precise mechanism is not known. epigallocatechin gallate 0-28 epidermal growth factor receptor Homo sapiens 118-156 17616711-1 2007 (-)-Epigallocatechin gallate (EGCG), a major biologically active constituent of green tea, inhibits activation of the epidermal growth factor (EGF) receptor (EGFR) and downstream signaling pathways in several types of human cancer cells, but the precise mechanism is not known. epigallocatechin gallate 0-28 epidermal growth factor receptor Homo sapiens 158-162 17616711-1 2007 (-)-Epigallocatechin gallate (EGCG), a major biologically active constituent of green tea, inhibits activation of the epidermal growth factor (EGF) receptor (EGFR) and downstream signaling pathways in several types of human cancer cells, but the precise mechanism is not known. epigallocatechin gallate 30-34 epidermal growth factor receptor Homo sapiens 118-156 17616711-1 2007 (-)-Epigallocatechin gallate (EGCG), a major biologically active constituent of green tea, inhibits activation of the epidermal growth factor (EGF) receptor (EGFR) and downstream signaling pathways in several types of human cancer cells, but the precise mechanism is not known. epigallocatechin gallate 30-34 epidermal growth factor receptor Homo sapiens 158-162 17616711-5 2007 Pretreatment with EGCG inhibited the binding of Alexa Fluor 488-labeled EGF to the cells and also inhibited EGF-induced dimerization of the EGFR. epigallocatechin gallate 18-22 epidermal growth factor receptor Homo sapiens 140-144 17616711-9 2007 Taken together, these findings suggest that EGCG inhibits the binding of EGF to the EGFR and the subsequent dimerization and activation of the EGFR by altering membrane organization. epigallocatechin gallate 44-48 epidermal growth factor receptor Homo sapiens 84-88 17616711-9 2007 Taken together, these findings suggest that EGCG inhibits the binding of EGF to the EGFR and the subsequent dimerization and activation of the EGFR by altering membrane organization. epigallocatechin gallate 44-48 epidermal growth factor receptor Homo sapiens 143-147 16404708-4 2006 The experimental data indicated that the molecular mechanisms of fatty acid synthase gene suppression by tea polyphenols (EGCG, theaflavins) may invite down-regulation of EGFR/PI3K/Akt/Sp-1 signal transduction pathways. epigallocatechin gallate 122-126 epidermal growth factor receptor Homo sapiens 171-175 17539658-3 2007 Our previous study demonstrated that (-)-epigallocatechin 3-gallate (EGCG), the green tea catechin, could down-regulate FAS expression by suppressing EGFR (epidermal growth factor receptor) signaling and downstream phosphatidylinositol 3-kinase (PI3K)/Akt activation in the MCF-7 breast cancer cell line. epigallocatechin gallate 37-67 epidermal growth factor receptor Homo sapiens 150-154 17539658-3 2007 Our previous study demonstrated that (-)-epigallocatechin 3-gallate (EGCG), the green tea catechin, could down-regulate FAS expression by suppressing EGFR (epidermal growth factor receptor) signaling and downstream phosphatidylinositol 3-kinase (PI3K)/Akt activation in the MCF-7 breast cancer cell line. epigallocatechin gallate 37-67 epidermal growth factor receptor Homo sapiens 156-188 17539658-3 2007 Our previous study demonstrated that (-)-epigallocatechin 3-gallate (EGCG), the green tea catechin, could down-regulate FAS expression by suppressing EGFR (epidermal growth factor receptor) signaling and downstream phosphatidylinositol 3-kinase (PI3K)/Akt activation in the MCF-7 breast cancer cell line. epigallocatechin gallate 69-73 epidermal growth factor receptor Homo sapiens 150-154 17539658-3 2007 Our previous study demonstrated that (-)-epigallocatechin 3-gallate (EGCG), the green tea catechin, could down-regulate FAS expression by suppressing EGFR (epidermal growth factor receptor) signaling and downstream phosphatidylinositol 3-kinase (PI3K)/Akt activation in the MCF-7 breast cancer cell line. epigallocatechin gallate 69-73 epidermal growth factor receptor Homo sapiens 156-188 17539658-4 2007 Herein, we examined the effects of EGCG on FAS expression modulated by another member of the erbB family, that is, HER2 or HER3. epigallocatechin gallate 35-39 epidermal growth factor receptor Homo sapiens 93-97 15814656-0 2005 (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. epigallocatechin gallate 0-28 epidermal growth factor receptor Homo sapiens 83-115 16053920-2 2005 We previously reported that in the HT29 human colon cancer cell line EGCG, the major biologically active component of green tea, inhibits activation of the RTKs EGFR, HER2, and HER3, and that this is associated with inhibition of multiple downstream signaling pathways. epigallocatechin gallate 69-73 epidermal growth factor receptor Homo sapiens 161-165 16140980-0 2005 Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. epigallocatechin gallate 23-53 epidermal growth factor receptor Homo sapiens 96-128 16140980-1 2005 (-)-Epigallocatechin-3-gallate (EGCG), the principal polyphenol in green tea, has been shown to inhibit the growth of many cancer cell lines and to suppress the phosphorylation of epidermal growth factor receptor (EGFR). epigallocatechin gallate 0-30 epidermal growth factor receptor Homo sapiens 180-212 16140980-1 2005 (-)-Epigallocatechin-3-gallate (EGCG), the principal polyphenol in green tea, has been shown to inhibit the growth of many cancer cell lines and to suppress the phosphorylation of epidermal growth factor receptor (EGFR). epigallocatechin gallate 0-30 epidermal growth factor receptor Homo sapiens 214-218 16140980-1 2005 (-)-Epigallocatechin-3-gallate (EGCG), the principal polyphenol in green tea, has been shown to inhibit the growth of many cancer cell lines and to suppress the phosphorylation of epidermal growth factor receptor (EGFR). epigallocatechin gallate 32-36 epidermal growth factor receptor Homo sapiens 180-212 16140980-1 2005 (-)-Epigallocatechin-3-gallate (EGCG), the principal polyphenol in green tea, has been shown to inhibit the growth of many cancer cell lines and to suppress the phosphorylation of epidermal growth factor receptor (EGFR). epigallocatechin gallate 32-36 epidermal growth factor receptor Homo sapiens 214-218 16140980-3 2005 Pretreatment of KYSE 150 cells with EGCG (20 micromol/L) for 0.5 to 24 hours in HAM"s F12 and RPMI 1640 mixed medium at 37 degrees C, before the addition of EGF, resulted in a decreased level of phosphorylated EGFR (by 32-85%). epigallocatechin gallate 36-40 epidermal growth factor receptor Homo sapiens 210-214 16140980-4 2005 Prolonged treatment with EGCG (8 or 24 hours) also decreased EGFR protein level (both by 80%). epigallocatechin gallate 25-29 epidermal growth factor receptor Homo sapiens 61-65 16140980-12 2005 The results suggest that in cell culture conditions, the auto-oxidation of EGCG leads to EGFR inactivation, but the inhibition of cell growth is due to other mechanisms. epigallocatechin gallate 75-79 epidermal growth factor receptor Homo sapiens 89-93 15814656-1 2005 PURPOSE: (-)-Epigallocatechin gallate (EGCG) inhibits activation of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) and multiple downstream signaling pathways in cancer cell lines. epigallocatechin gallate 9-37 epidermal growth factor receptor Homo sapiens 72-104 15814656-1 2005 PURPOSE: (-)-Epigallocatechin gallate (EGCG) inhibits activation of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) and multiple downstream signaling pathways in cancer cell lines. epigallocatechin gallate 9-37 epidermal growth factor receptor Homo sapiens 106-110 15814656-1 2005 PURPOSE: (-)-Epigallocatechin gallate (EGCG) inhibits activation of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) and multiple downstream signaling pathways in cancer cell lines. epigallocatechin gallate 39-43 epidermal growth factor receptor Homo sapiens 72-104 15814656-1 2005 PURPOSE: (-)-Epigallocatechin gallate (EGCG) inhibits activation of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) and multiple downstream signaling pathways in cancer cell lines. epigallocatechin gallate 39-43 epidermal growth factor receptor Homo sapiens 106-110 15814656-6 2005 Both EGCG and Poly E caused a decrease in the phosphorylated forms of EGFR and HER2 proteins, and subsequently caused a decrease in the phosphorylated forms of the extracellular signal-regulated kinase and Akt proteins. epigallocatechin gallate 5-9 epidermal growth factor receptor Homo sapiens 70-74 15814656-10 2005 Furthermore, when treatment was prolonged for 96 hours, 1 microg/mL of EGCG or Poly E was sufficient to inhibit growth, reduce activation of EGFR and HER2, and induce apoptosis. epigallocatechin gallate 71-75 epidermal growth factor receptor Homo sapiens 141-145 16416603-5 2005 Treatment of these cells with 20 microg/ml of EGCG (the IC50 concentration for growth inhibition) caused, within 6 hours, a decrease in the phosphorylated (i.e. activated) forms of not only EGFR and HER2, but also HER3. epigallocatechin gallate 46-50 epidermal growth factor receptor Homo sapiens 190-194 16416603-10 2005 With a longer incubation time, 96 hours, a very low dose (1.0 microg/ml) of EGCG also caused inhibition of cell growth, inhibition of activation of EGFR, HER2, and HER3, a decrease in the levels of COX-2 and Bcl-xL proteins, and apoptosis. epigallocatechin gallate 76-80 epidermal growth factor receptor Homo sapiens 148-152 16416603-11 2005 These results provide the first evidence that a low concentration of EGCG can inhibit activation of, at least, three members of the EGFR family of RTKs, and also inhibit COX-2 expression in colon cancer cells. epigallocatechin gallate 69-73 epidermal growth factor receptor Homo sapiens 132-136 11751523-8 2001 Treatment with EGCG inhibited phosphorylation of the EGFR, signal transducer and activator of transcription3 (Stat3), and extracellular regulated kinase (ERK) proteins and also inhibited basal and transforming growth factor-alpha-stimulated c-fos and cyclin D1 promoter activity. epigallocatechin gallate 15-19 epidermal growth factor receptor Homo sapiens 53-57 14701854-0 2004 Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. epigallocatechin gallate 0-26 epidermal growth factor receptor Homo sapiens 36-68 14701854-4 2004 In the present study, we investigated the effects of epigallocatechin-3-gallate (EGCG), a bioactive green tea polyphenol, on EGFR signaling in cervical cells. epigallocatechin gallate 53-79 epidermal growth factor receptor Homo sapiens 125-129 14701854-4 2004 In the present study, we investigated the effects of epigallocatechin-3-gallate (EGCG), a bioactive green tea polyphenol, on EGFR signaling in cervical cells. epigallocatechin gallate 81-85 epidermal growth factor receptor Homo sapiens 125-129 14701854-5 2004 EGCG inhibits epidermal growth factor-dependent activation of EGFR, and EGFR-dependent activation of the mitogen-activated protein kinases ERK1/2. epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 62-66 14701854-6 2004 EGCG also inhibits EGFR-dependent AKT activity. epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 19-23 12440226-0 2002 Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. epigallocatechin gallate 0-26 epidermal growth factor receptor Homo sapiens 111-115 12440226-1 2002 In a recent study on head and neck squamous cell carcinoma (HNSCC) cells we found that epigallocatechin-3-gallate (EGCG), a major biologically active component of green tea, inhibited activation of the epidermal growth factor receptor (EGFR) and related signaling pathways. epigallocatechin gallate 87-113 epidermal growth factor receptor Homo sapiens 202-234 12440226-1 2002 In a recent study on head and neck squamous cell carcinoma (HNSCC) cells we found that epigallocatechin-3-gallate (EGCG), a major biologically active component of green tea, inhibited activation of the epidermal growth factor receptor (EGFR) and related signaling pathways. epigallocatechin gallate 87-113 epidermal growth factor receptor Homo sapiens 236-240 12440226-1 2002 In a recent study on head and neck squamous cell carcinoma (HNSCC) cells we found that epigallocatechin-3-gallate (EGCG), a major biologically active component of green tea, inhibited activation of the epidermal growth factor receptor (EGFR) and related signaling pathways. epigallocatechin gallate 115-119 epidermal growth factor receptor Homo sapiens 202-234 12440226-1 2002 In a recent study on head and neck squamous cell carcinoma (HNSCC) cells we found that epigallocatechin-3-gallate (EGCG), a major biologically active component of green tea, inhibited activation of the epidermal growth factor receptor (EGFR) and related signaling pathways. epigallocatechin gallate 115-119 epidermal growth factor receptor Homo sapiens 236-240 12440226-3 2002 Treatment with EGCG inhibited the constitutive activation of the EGFR, Stat3, and Akt in both cell lines. epigallocatechin gallate 15-19 epidermal growth factor receptor Homo sapiens 65-69 16416603-3 2005 We previously reported that in HT29 human colon cancer cells EGCG, the major biologically active component of green tea, inhibits activation of two members of this family, EGFR and HER2, and multiple downstream signaling pathways. epigallocatechin gallate 61-65 epidermal growth factor receptor Homo sapiens 172-176 15147726-9 2004 Meanwhile, EGCG inhibited EGFR promoter activity and EGFR phosphorylation. epigallocatechin gallate 11-15 epidermal growth factor receptor Homo sapiens 26-30 15147726-9 2004 Meanwhile, EGCG inhibited EGFR promoter activity and EGFR phosphorylation. epigallocatechin gallate 11-15 epidermal growth factor receptor Homo sapiens 53-57 15147726-11 2004 This inhibition of LMP1-caused NF-kappaB activation was mediated via the phosphorylative degradation of its inhibitory protein IkappaBalpha, and then EGCG inhibited EGFR activity which was a downstream gene from NF-kappaB. epigallocatechin gallate 150-154 epidermal growth factor receptor Homo sapiens 165-169 11007941-10 2000 In androgen-independent human prostate carcinoma DU145 cells, silymarin, genistein, and EGCG resulted in a significant to complete inhibition of transforming growth factor-alpha-caused activation of membrane receptor erbB1 followed by inhibition of downstream cytoplasmic signaling target Shc activation and a decrease in its binding with erbB1, without an alteration in their protein expression. epigallocatechin gallate 88-92 epidermal growth factor receptor Homo sapiens 217-222 11170137-6 2001 RESULTS: Treatment of cells with silymarin, genistein or EGCG at 100-200 microM resulted in a complete inhibition of TGFalpha-caused activation of erbB1 followed by a moderate to strong inhibition (10-90%) of Shc activation without an alteration in their protein levels. epigallocatechin gallate 57-61 epidermal growth factor receptor Homo sapiens 147-152 11007941-10 2000 In androgen-independent human prostate carcinoma DU145 cells, silymarin, genistein, and EGCG resulted in a significant to complete inhibition of transforming growth factor-alpha-caused activation of membrane receptor erbB1 followed by inhibition of downstream cytoplasmic signaling target Shc activation and a decrease in its binding with erbB1, without an alteration in their protein expression. epigallocatechin gallate 88-92 epidermal growth factor receptor Homo sapiens 339-344 10223207-1 1999 Previous studies in our laboratory have shown that the major green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG), suppressed autophosphorylation of epidermal growth factor (EGF) receptor induced by EGF in human A431 epidermoid carcinoma cells. epigallocatechin gallate 83-113 epidermal growth factor receptor Homo sapiens 156-194 10223207-1 1999 Previous studies in our laboratory have shown that the major green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG), suppressed autophosphorylation of epidermal growth factor (EGF) receptor induced by EGF in human A431 epidermoid carcinoma cells. epigallocatechin gallate 115-119 epidermal growth factor receptor Homo sapiens 156-194 9328839-5 1997 In vitro assay, EGCG strongly inhibited the protein tyrosine kinase (PTK) activities of EGF-R, PDGF-R, and FGF-R, and exhibited an IC50 value of 0.5-1 microgram/ml. epigallocatechin gallate 16-20 epidermal growth factor receptor Homo sapiens 88-93 9328839-7 1997 In an in vivo assay, EGCG could reduce the autophosphorylation level of EGF-R by EGF. epigallocatechin gallate 21-25 epidermal growth factor receptor Homo sapiens 72-77 9328839-8 1997 Phosphoamino acid analysis of the EGF-R revealed that EGCG inhibited the EGF-stimulated increase in phosphotyrosine level in A431 cells. epigallocatechin gallate 54-58 epidermal growth factor receptor Homo sapiens 34-39 9328839-10 1997 The results of further studies suggested that the inhibition of proliferation and suppression of the EGF signaling by EGCG might mainly mediate dose-dependent blocking of ligand binding to its receptor, and subsequently through inhibition of EGF-R kinase activity. epigallocatechin gallate 118-122 epidermal growth factor receptor Homo sapiens 242-247 34769263-0 2021 Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer. epigallocatechin gallate 10-36 epidermal growth factor receptor Homo sapiens 40-44 34769263-3 2021 Epigallocatechin-3-gallate (EGCG), the main bioactive molecule in green tea, acts as a tyrosine kinase inhibitor toward cancer cells overexpressing EGFR (wild-type). epigallocatechin gallate 0-26 epidermal growth factor receptor Homo sapiens 148-152 34769263-3 2021 Epigallocatechin-3-gallate (EGCG), the main bioactive molecule in green tea, acts as a tyrosine kinase inhibitor toward cancer cells overexpressing EGFR (wild-type). epigallocatechin gallate 28-32 epidermal growth factor receptor Homo sapiens 148-152 34769263-4 2021 However, little information has been reported on the effect of EGCG on EGFR with activating mutations. epigallocatechin gallate 63-67 epidermal growth factor receptor Homo sapiens 71-75 34769263-5 2021 In this study, we evaluated the ability of EGCG to inhibit EGFR signaling activation in three different NSCLC cell lines containing wild-type EGFR or EGFR with additional mutations. epigallocatechin gallate 43-47 epidermal growth factor receptor Homo sapiens 59-63 33587351-2 2021 Amphiregulin (AREG) is the most abundant epidermal growth factor receptor (EGFR) agonist in MDA-MB-231 TNBC cells, whose proliferation can be inhibited by (-)-epigallocatechin gallate (EGCG), a constituent of green tea that is prone to oxidative polymerization. epigallocatechin gallate 155-183 epidermal growth factor receptor Homo sapiens 41-73 34299635-0 2021 Novel Perbutyrylated Glucose Derivatives of (-)-Epigallocatechin-3-Gallate Inhibit Cancer Cells Proliferation by Decreasing Phosphorylation of the EGFR: Synthesis, Cytotoxicity, and Molecular Docking. epigallocatechin gallate 44-74 epidermal growth factor receptor Homo sapiens 147-151 34299635-8 2021 Compounds 11 and 12 decreased phosphorylation of EGFR and downstream signaling protein, which also have more hydrophobic interactions than EGCG by docking study. epigallocatechin gallate 139-143 epidermal growth factor receptor Homo sapiens 49-53 33587351-2 2021 Amphiregulin (AREG) is the most abundant epidermal growth factor receptor (EGFR) agonist in MDA-MB-231 TNBC cells, whose proliferation can be inhibited by (-)-epigallocatechin gallate (EGCG), a constituent of green tea that is prone to oxidative polymerization. epigallocatechin gallate 155-183 epidermal growth factor receptor Homo sapiens 75-79 33587351-2 2021 Amphiregulin (AREG) is the most abundant epidermal growth factor receptor (EGFR) agonist in MDA-MB-231 TNBC cells, whose proliferation can be inhibited by (-)-epigallocatechin gallate (EGCG), a constituent of green tea that is prone to oxidative polymerization. epigallocatechin gallate 185-189 epidermal growth factor receptor Homo sapiens 41-73 33587351-2 2021 Amphiregulin (AREG) is the most abundant epidermal growth factor receptor (EGFR) agonist in MDA-MB-231 TNBC cells, whose proliferation can be inhibited by (-)-epigallocatechin gallate (EGCG), a constituent of green tea that is prone to oxidative polymerization. epigallocatechin gallate 185-189 epidermal growth factor receptor Homo sapiens 75-79 33587351-6 2021 Levels of EGFR and p44/42 MAPK phosphorylation in MDA-MB-231 cells were significantly reduced by treatment with 10 muM dimeric-EGCG (P < 0.01). epigallocatechin gallate 127-131 epidermal growth factor receptor Homo sapiens 10-14 33587351-8 2021 Surface plasmon resonance analysis demonstrated that 10 muM dimeric-EGCG bound directly to the extracellular domain of EGFR, competitively inhibiting the binding of AREG to EGFR. epigallocatechin gallate 68-72 epidermal growth factor receptor Homo sapiens 119-123 33587351-8 2021 Surface plasmon resonance analysis demonstrated that 10 muM dimeric-EGCG bound directly to the extracellular domain of EGFR, competitively inhibiting the binding of AREG to EGFR. epigallocatechin gallate 68-72 epidermal growth factor receptor Homo sapiens 173-177 35063850-5 2022 EGCG initiates cell death through the intrinsic pathway and causes inhibition of EGFR, STAT3, and ERK pathways in several cancers. epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 81-85 35211881-9 2022 Molecular docking analysis showed combinations between these targets and EGCG, and the interaction between EGCG and the targets IL-6 and EGFR was confirmed by using molecular dynamic simulation. epigallocatechin gallate 107-111 epidermal growth factor receptor Homo sapiens 137-141 32217102-0 2020 The inhibitory effect of ECG and EGCG dimeric procyanidins on colorectal cancer cells growth is associated with their actions at lipid rafts and the inhibition of the epidermal growth factor receptor signaling. epigallocatechin gallate 33-37 epidermal growth factor receptor Homo sapiens 167-199 32217102-7 2020 Mechanistically, ECG and EGCG dimers inhibited the activation of lipid raft-associated epidermal growth factor (EGF) receptor (EGFR), without affecting its localization at lipid rafts. epigallocatechin gallate 25-29 epidermal growth factor receptor Homo sapiens 87-125 32217102-7 2020 Mechanistically, ECG and EGCG dimers inhibited the activation of lipid raft-associated epidermal growth factor (EGF) receptor (EGFR), without affecting its localization at lipid rafts. epigallocatechin gallate 25-29 epidermal growth factor receptor Homo sapiens 127-131 32217102-8 2020 In particular, ECG and EGCG dimers reduced EGFR phosphorylation at Tyr1068 residue, prevented EGFR dimerization and activation upon stimulation, and induced EGFR internalization both in the absence and presence of EGF. epigallocatechin gallate 23-27 epidermal growth factor receptor Homo sapiens 43-47 32217102-8 2020 In particular, ECG and EGCG dimers reduced EGFR phosphorylation at Tyr1068 residue, prevented EGFR dimerization and activation upon stimulation, and induced EGFR internalization both in the absence and presence of EGF. epigallocatechin gallate 23-27 epidermal growth factor receptor Homo sapiens 94-98 32217102-8 2020 In particular, ECG and EGCG dimers reduced EGFR phosphorylation at Tyr1068 residue, prevented EGFR dimerization and activation upon stimulation, and induced EGFR internalization both in the absence and presence of EGF. epigallocatechin gallate 23-27 epidermal growth factor receptor Homo sapiens 94-98 32217102-9 2020 Furthermore, ECG and EGCG dimers increased EGFR phosphorylation at Tyr1045 residue, providing a docking site for ubiquitin ligase c-Cbl and induced EGFR degradation by the proteasome. epigallocatechin gallate 21-25 epidermal growth factor receptor Homo sapiens 43-47 32217102-9 2020 Furthermore, ECG and EGCG dimers increased EGFR phosphorylation at Tyr1045 residue, providing a docking site for ubiquitin ligase c-Cbl and induced EGFR degradation by the proteasome. epigallocatechin gallate 21-25 epidermal growth factor receptor Homo sapiens 148-152 32217102-11 2020 In conclusion, ECG and EGCG dimers reduced CRC cell growth by inhibiting EGFR activation at multiple steps, including the disruption of lipid rafts integrity and promoting EGFR degradation. epigallocatechin gallate 23-27 epidermal growth factor receptor Homo sapiens 73-77 32217102-11 2020 In conclusion, ECG and EGCG dimers reduced CRC cell growth by inhibiting EGFR activation at multiple steps, including the disruption of lipid rafts integrity and promoting EGFR degradation. epigallocatechin gallate 23-27 epidermal growth factor receptor Homo sapiens 172-176 31934166-9 2019 This is the first evidence that EGCG exerts its anti-cancer effect by inhibiting ERalpha36, followed with inhibition of the ERalpha36-EGFR-Her-2 feedback loop and PI3K/Akt, MAPK/ERK pathway, activation of caspase 3, and accumulation of p-ERK in cytoplasm. epigallocatechin gallate 32-36 epidermal growth factor receptor Homo sapiens 134-138 32138321-0 2020 Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents. epigallocatechin gallate 85-111 epidermal growth factor receptor Homo sapiens 42-46 31979082-6 2020 EGCG has been reported as a promising target for plasma membrane proteins, such as epidermal growth factor receptor (EGFR). epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 83-115 31979082-6 2020 EGCG has been reported as a promising target for plasma membrane proteins, such as epidermal growth factor receptor (EGFR). epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 117-121 31188490-2 2019 The active ingredient, (-)-epigallocatechin gallate (EGCG), is a major polyphenol demonstrated to inhibit the growth of various non-oral cancer cell lines and interfere with the carcinogenic process, including downregulation of the epidermal growth factor receptor (EGFR). epigallocatechin gallate 23-51 epidermal growth factor receptor Homo sapiens 266-270 31188490-2 2019 The active ingredient, (-)-epigallocatechin gallate (EGCG), is a major polyphenol demonstrated to inhibit the growth of various non-oral cancer cell lines and interfere with the carcinogenic process, including downregulation of the epidermal growth factor receptor (EGFR). epigallocatechin gallate 23-51 epidermal growth factor receptor Homo sapiens 232-264 31188490-2 2019 The active ingredient, (-)-epigallocatechin gallate (EGCG), is a major polyphenol demonstrated to inhibit the growth of various non-oral cancer cell lines and interfere with the carcinogenic process, including downregulation of the epidermal growth factor receptor (EGFR). epigallocatechin gallate 53-57 epidermal growth factor receptor Homo sapiens 232-264 31188490-2 2019 The active ingredient, (-)-epigallocatechin gallate (EGCG), is a major polyphenol demonstrated to inhibit the growth of various non-oral cancer cell lines and interfere with the carcinogenic process, including downregulation of the epidermal growth factor receptor (EGFR). epigallocatechin gallate 53-57 epidermal growth factor receptor Homo sapiens 266-270 30858760-0 2019 Epigallocatechin-3-gallate inhibits the growth and increases the apoptosis of human thyroid carcinoma cells through suppression of EGFR/RAS/RAF/MEK/ERK signaling pathway. epigallocatechin gallate 0-26 epidermal growth factor receptor Homo sapiens 131-135 30858760-13 2019 EGCG reduced the protein levels of phospho (p)-epidermal growth factor receptor (EGFR), H-RAS, p-RAF, p-MEK1/2, and p-extracellular signal-regulated protein kinase 1/2 (ERK1/2) in human thyroid carcinoma cells. epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 47-79 30858760-13 2019 EGCG reduced the protein levels of phospho (p)-epidermal growth factor receptor (EGFR), H-RAS, p-RAF, p-MEK1/2, and p-extracellular signal-regulated protein kinase 1/2 (ERK1/2) in human thyroid carcinoma cells. epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 81-85 30858760-15 2019 Conclusions: EGCG could reduce the growth and increase the apoptosis of human thyroid carcinoma cells through suppressing the EGFR/RAS/RAF/MEK/ERK signaling pathway. epigallocatechin gallate 13-17 epidermal growth factor receptor Homo sapiens 126-130 29329808-4 2018 Herein we combined structural data and molecular dynamics (MD) simulations coupled to an MMGBSA approach to provide insight into the binding mechanism between two dual synthetics (lapatinib and TAK-285) and one dual natural inhibitor (EGCG) which target EGFR/HER2. epigallocatechin gallate 235-239 epidermal growth factor receptor Homo sapiens 254-258 31223050-0 2019 QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor. epigallocatechin gallate 110-134 epidermal growth factor receptor Homo sapiens 158-190 31223050-0 2019 QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor. epigallocatechin gallate 136-140 epidermal growth factor receptor Homo sapiens 158-190 31223050-1 2019 Epigallocatechin gallate (EGCG) is a major polyphenols of green tea may have the possibility to inhibit epidermal growth factor receptor (EGFR) activity and lead to reduce non-small cell lung cancer (NSCLC) progression. epigallocatechin gallate 0-24 epidermal growth factor receptor Homo sapiens 104-136 31223050-1 2019 Epigallocatechin gallate (EGCG) is a major polyphenols of green tea may have the possibility to inhibit epidermal growth factor receptor (EGFR) activity and lead to reduce non-small cell lung cancer (NSCLC) progression. epigallocatechin gallate 0-24 epidermal growth factor receptor Homo sapiens 138-142 31223050-1 2019 Epigallocatechin gallate (EGCG) is a major polyphenols of green tea may have the possibility to inhibit epidermal growth factor receptor (EGFR) activity and lead to reduce non-small cell lung cancer (NSCLC) progression. epigallocatechin gallate 26-30 epidermal growth factor receptor Homo sapiens 104-136 31223050-1 2019 Epigallocatechin gallate (EGCG) is a major polyphenols of green tea may have the possibility to inhibit epidermal growth factor receptor (EGFR) activity and lead to reduce non-small cell lung cancer (NSCLC) progression. epigallocatechin gallate 26-30 epidermal growth factor receptor Homo sapiens 138-142 31223050-3 2019 In this examination, integration of quantitative structure-activity relationship (QSAR) modeling, pharmacophore-based virtual screening, and ensemble docking approaches were used to predict potential novel EGCG analogs as effective EGFR inhibitors. epigallocatechin gallate 206-210 epidermal growth factor receptor Homo sapiens 232-236 31223050-5 2019 Virtual screening and docking studies revealed that seven high potential EGCG analogs as strong EGFR binders. epigallocatechin gallate 73-77 epidermal growth factor receptor Homo sapiens 96-100 31223050-8 2019 Therefore, this can characterize as a block-cluster mechanism between EGCG analogs and EGFR complexes. epigallocatechin gallate 70-74 epidermal growth factor receptor Homo sapiens 87-91 29157036-6 2018 Our data suggest that EGCG administration might reduce the unfavourable traits, particularly associated with ErbB1/EGFR overexpression. epigallocatechin gallate 22-26 epidermal growth factor receptor Homo sapiens 109-114 29157036-6 2018 Our data suggest that EGCG administration might reduce the unfavourable traits, particularly associated with ErbB1/EGFR overexpression. epigallocatechin gallate 22-26 epidermal growth factor receptor Homo sapiens 115-119 28465354-0 2017 EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion. epigallocatechin gallate 19-49 epidermal growth factor receptor Homo sapiens 0-4 29276223-0 2017 Effects of (-)-epigallocatechin-3-gallate on EGFR- or Fusion Gene-driven Lung Cancer Cells. epigallocatechin gallate 11-41 epidermal growth factor receptor Homo sapiens 45-49 28432554-3 2017 However, in the presence of epigallocatechin-3-gallate (EGCG), a polyphenol in green tea, BEAS-2B cells resisted LPS-induced apoptosis and restored the expression of GRP and its downstream effectors such as epidermal growth factor receptor and NF-kappaB, as analysed by immunoblotting and qPCR. epigallocatechin gallate 28-54 epidermal growth factor receptor Homo sapiens 207-239 28432554-3 2017 However, in the presence of epigallocatechin-3-gallate (EGCG), a polyphenol in green tea, BEAS-2B cells resisted LPS-induced apoptosis and restored the expression of GRP and its downstream effectors such as epidermal growth factor receptor and NF-kappaB, as analysed by immunoblotting and qPCR. epigallocatechin gallate 56-60 epidermal growth factor receptor Homo sapiens 207-239 28247504-3 2017 Co-treatment with 5 microM BaP and 20 microM EGCG in BEAS-2B promoted a significant reduction in cell viability and greater G2/M cell cycle arrest, induction of ROS, and reductions in BaP-induced CYP1A1/CYP1B1/COMT, EGFR, p-Akt (Ser473), p-p53 (Thr55), and survivin mRNA/protein expression, as well as an increase in p-p53 (Ser15). epigallocatechin gallate 45-49 epidermal growth factor receptor Homo sapiens 216-220 28247504-8 2017 Therefore, EGCG was found to promote greater cytotoxicity to BEAS-2B co-treated with BaP and BEAS-2BBaP upon gefitinib co-treatment through regulating metabolism enzymes and signaling pathways involving EGFR and p53. epigallocatechin gallate 11-15 epidermal growth factor receptor Homo sapiens 203-207 28487468-9 2017 EGCG exhibited similar paradoxical behavior in EGFR signaling. epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 47-51 28487468-10 2017 EGCG alters the topology of EGFR TMD and activates the receptor in the absence of EGF, but inhibits EGF-induced EGFR activation. epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 28-32 28487468-10 2017 EGCG alters the topology of EGFR TMD and activates the receptor in the absence of EGF, but inhibits EGF-induced EGFR activation. epigallocatechin gallate 0-4 epidermal growth factor receptor Homo sapiens 112-116 28465354-4 2017 The EGCG + IIF treatment was the most active in down-regulating EGFR phosphorylation at Tyr1068 in all the investigated cell lines; p473AKT was also down-regulated in MCF-TAM cells. epigallocatechin gallate 4-8 epidermal growth factor receptor Homo sapiens 64-68 28465354-7 2017 We considered that EGCG and IIF treatments could alter the molecular network based on EGFR, CD44 and EMMPRIN expression interdependence and reduced the migration tendency in MCF-7, MCF-7TAM and MDA-MB-231 cells. epigallocatechin gallate 19-23 epidermal growth factor receptor Homo sapiens 86-90 28286519-6 2017 In this paper we aim to review the involvement of ErbB proteins in cancer as well as the biologic activity of EGCG and curcumin in ErbB expressing and overexpressing malignancies. epigallocatechin gallate 110-114 epidermal growth factor receptor Homo sapiens 131-135 28485162-0 2017 Epigallocatechin gallate inhibits the growth of salivary adenoid cystic carcinoma cells via the EGFR/Erk signal transduction pathway and the mitochondria apoptosis pathway. epigallocatechin gallate 0-24 epidermal growth factor receptor Homo sapiens 96-100 28485162-6 2017 Furthermore, by Western blotting with antibodies specific for EGFR, Erk 1/2 (p-Erk 1/2), Mek (p-Mek), Bcl-2, and Bax, it was demonstrated that EGCG could reduce the expression of EGFR, inhibit phosphorylation of Erk 1/2 and Mek, downregulate Bcl-2, and upregulate Bax. epigallocatechin gallate 143-147 epidermal growth factor receptor Homo sapiens 62-66 28485162-6 2017 Furthermore, by Western blotting with antibodies specific for EGFR, Erk 1/2 (p-Erk 1/2), Mek (p-Mek), Bcl-2, and Bax, it was demonstrated that EGCG could reduce the expression of EGFR, inhibit phosphorylation of Erk 1/2 and Mek, downregulate Bcl-2, and upregulate Bax. epigallocatechin gallate 143-147 epidermal growth factor receptor Homo sapiens 179-183